Minerva Neurosciences Inc. could regain at least some of June's disappointing initial public offering (IPO) and better align its pipeline candidates, thanks to enthusiasm over preclinical data from nonhuman primates – marmosets – in Parkinson's disease (PD), results that let shares (NASDAQ:NERV) close Tuesday at $6.49, up 8.2 percent.